Tuesday, January 21, 2025

No Result

View All Result

Media

Support Us

No Result

View All Result

Health

Reference pricing will lead to poor access to critical drugs: John Adams in the Detroit News

November 21, 2024

John Adams

Columns

Pharmacare won’t help Canadians with rare disorders: Nigel Rawson and John Adams in the Financial Post

November 7, 2023

Columns

Americans look to Canada for lower drug prices, but are they getting the full picture?: Nigel Rawson and John Adams in The Hill

October 7, 2023

Commentary

Waiting for new drugs for rare disorders in Canada

September 6, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

August 30, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

August 23, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

August 16, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

August 9, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

July 26, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

July 19, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

July 12, 2023

The U.S. outsources control of drug prices to Canada: weird! Richard Owens in the Financial Post

Columns

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

March 1, 2023

Page 2 of 3 Prev 1 2 3 Next

Newsletter Signup

Email Address *

First Name *

Last Name *

*Required Fields

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

Reference pricing will lead to poor access to critical drugs: John Adams in the Detroit News

John Adams

Pharmacare won’t help Canadians with rare disorders: Nigel Rawson and John Adams in the Financial Post

Americans look to Canada for lower drug prices, but are they getting the full picture?: Nigel Rawson and John Adams in The Hill

Waiting for new drugs for rare disorders in Canada

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

Top News

Getting Canada back on track: How to build major projects in the coming decade: Jack Middleton

Empowering First Nations’ economic growth in Canada: Ken Coates and Kody Penner for Inside Policy Talks

The Reform Act could have saved Canada from Liberal leadership drama: David Livingstone for Inside Policy

Multimedia

Coleman Hughes and Abigail Shrier on Identity, Speech, and Policy: Voices that inspire

Karen Restoule on the challenges of Indigenous economic development in Canada: MLI in Parliament

Tariffs, Trump, and the Canadian oil and gas sector: Heather Exner-Pirot and Lisa Baiton for Inside Policy Talks

Justin Trudeau never really understood Canada: Christopher Dummitt in The Hub

Euthanasia and assisted dying – unmasking health care and social failures: Ramona Coelho

Don’t shoot yourself in the foot—and five other rules for negotiating with Trump: Fen Osler Hampson and Tim Sargent in The Hub

It’s time for Poilievre to speak up for Canada’s defence: J.L. Granatstein for Inside Policy

The politics of culture wars in contemporary Canada

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us